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Abstract 
BACKGROUND: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). 
Lipid changes related to inflammation have been described in RA. Methotrexate (MTX) treatment is effective in 
controlling inflammation and decreasing the CRP (C-reactive protein) values. 
AIM: To examine the disease activity, CRP and Apo B values in the detection of new patients with active and 
untreated RA, and impact of MTX therapy on their levels after 6 months and one year of treatment, and the 
correlation between their values in this period.  
METHODS: 80 patients with active and newly discovered RA patients who meet the American Rheumatology 
Association (ARA) 1987 revised criteria were treated with disease-modifying anti-inflammatory drugs (DMARDs) 
according to the protocol for treatment.  
RESULTS: After a year of therapy RA patients achieved significant decrease in the DAS28 (disease activity 
score) (p < 0.01 and p < 0.001), and CRP values (p < 0.001). Levels of Apo B values at the 12 months were 
nonsignificantly higher compared to the results obtained at the beginning of the study (p < 0.001). After 6 and 12 
months there was a weak nonsignificant negative correlation about the values of CRP and Apo B at baseline and 
after 12 months (r = –0.15 and r = -0.12 p > 0.05).  
CONCLUSION: Use of MTX therapy at RA patients had a reduced effect on disease activity and inflammation, 
but the nonsignificance effect on the values of Apo B lipoproteins. 
 
 
 
 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA), a chronic 
inflammatory joint disease of unknown aetiology, 
affects approximately one per cent of the general 
population. Estimated standardised mortality ratio’s 
associated with RA range from 1.3 to 3.0. This 
increased mortality is largely attributable to CVD, 
particularly coronary atherosclerosis. The 
cardiovascular morbidity found in RA patients appears 
to be increased by twofold or more compared to the 
general population (age and sex-matched) [1], [2], [3], 
[4], [5]. 
Autoimmunity and inflammation play a major 
role in the development of atherosclerotic plaque 
formation in many rheumatological conditions 
including RA. The mechanisms underlying these 
changes include the interplay of inflammation and 
autoantibody formation. Thus treatment options to 
reduce CVD risk amongst these conditions share a 
common theme, with the use of DMARDs paramount 
to all [3], [5], [6]. 
Atherosclerosis is an inflammatory condition, 
with high inflammatory level implicated for developing 
CVD. Inflammatory markers such as IL-6, CRP and 
fibrinogen are associated with a high frequency of 
cardiovascular events. In particular, CRP has received 
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large attention due to its ability to independently 
predict cardiovascular events in the general 
population, which may in part, be due to its ability to 
directly contribute to the onset of CVD [7], [8], [9]. 
In RA patients, inflammatory markers such as 
the CRP and erythrocyte sedimentation rate are 
elevated and remain greater even in periods of low 
disease activity when compared to the general 
population. In patients with inflammatory arthritis who 
were followed up for 10 years, CRP levels 
independently predicted CVD mortality. The 
similarities between the inflammatory process of RA 
and atherosclerosis are remarkable. In both diseases, 
concentrations of IL-6, CRP and TNF-α are elevated, 
and both have similar patterns of activation for T-cells 
and macrophages [8], 10], [11]. 
Apolipoproteins are found on the surface of 
lipoproteins and regulate lipid metabolism. The 
apolipoproteins that are of clinical interest are apo B 
and apolipoprotein A1 (Apo A1). Apo B is found on 
LDL particles and is responsible for the clearance of 
LDL cholesterol through the LDL receptor pathway 
[12]. 
Apolipoprotein-related Mortality Risk 
(AMORIS) study investigated the use of apo B, Apo 
A1, and the apo B: apo A1 ratio at predicting fatal 
myocardial infarction (MI). The study followed 75 553 
Swedish men and women from 1985 to 1996. The 
authors found that apo B and the apo B: apo A1 ratio 
were both strongly predictive of increased risk of fatal 
MI in both men and women. Furthermore, they found 
that apo B was a stronger predictor of the risk of fatal 
MI than LDL cholesterol. However, apo B, although a 
strong predictor of coronary heart disease, is not 
currently recommended as the primary target of 
therapy and there is not enough evidence to justify 
apo B replacing LDL cholesterol as the preferred 
target of therapy by National Cholesterol Education 
Program Expert Panel on Detection, Evaluation, and 
Treatment of High Cholesterol in Adults (NCEP/ATP 
III) guidelines [1], [13], [14], [15]. 
Traditional synthetic DMARDs, such as MTX, 
Sulfasalazine and Hydroxychloroquine, have a 
protective role against CV risk. The mechanisms by 
which DMARD use influences CV risk are poorly 
understood, but lend support to the hypothesis that 
reducing inflammation is important in reducing CV 
risk. Of the traditional DMARDs, MTX is the most 
widely used and is known as the anchor drug in RA, 
yet the mechanisms underlying its anti-inflammatory 
properties are not fully understood [17]. 
Given the high level of systemic inflammatory 
burden that characterises RA, which is regarded as a 
key CV risk factor, alongside an increased prevalence 
of traditional risk factors, EULAR recommendations 
highlight the importance of adequate disease control 
to lower CV risk. The vulnerability of the carotid 
plaque is influenced by RA disease activity, and 
remission may alleviate this threat. Therefore, 
effective CV risk management will likely comprise not 
only adequate treatment of conventional risk factors 
but also tight and sustained disease activity control 
[6], [7], [18]. 
The purpose of this study is to examine the 
disease activity, CRP and Apo B values in the 
detection of new patients with active and untreated 
RA, and impact of MTX therapy on their levels at the 
same patients after 6 months and one year of 
treatment, and correlation between their values in this 
period. 
 
 
Material and Methods 
 
Inclusion criteria for patients 
Eighty consecutive, unselected patients who 
were referred to the outpatient rheumatology clinic at 
the Clinical Center in Skopje were investigated. All 
patients fulfilled the American College of 
Rheumatology (ACR) 1987 criteria for RA, had an 
early disease with disease duration of less than one 
year without prior use of DMARDs and or systemic 
steroids [24]. 
 
Exclusion criteria for patients 
Smokers or patients suffering from conditions 
that affect the lipid profile, such as diabetes mellitus, 
hypothyroidism, liver or kidney disease, Cushing's 
syndrome, Carcinoma, obesity (body mass index > 
30) and a history of familial dyslipidemia, were 
excluded. Also, patients receiving medications 
affecting lipid metabolisms, such as lipid-lowering 
drugs, beta-blockers, oral contraceptives, estrogen, 
progestin, thyroxin and vitamin E, were excluded from 
the study [9]. 
Thirty healthy, non-smoking volunteers also 
participated in the study and were used as a control 
group and fulfilled the same exclusion criteria reported 
for the patient group. None of the subjects 
participating in the control group had a history of CVD. 
The control group was proportionally matched for age 
and sex to the patient group. All controls reported no 
significant changes in their body weight for at least 
three months before entry to the study. All patients 
and controls gave informed consent, and the study 
protocol was approved by the Institutional Ethics 
Committee [21]. 
 
Study design 
Patients were treated with methotrexate 
(MTX; 0.2-0.6 mg/kg/week; mean ± standard deviation 
15.5 ± 1.3). Disease activity was assessed by 
measuring the disease activity for 28 joint indices 
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score (DAS-28), while the clinical response was 
evaluated according to the ACR 50% response 
criteria. All patients were followed up every month for 
the first three months, and every three months after 
that. During the follow-up period, a questionnaire 
concerning changes in dietary habits was carefully 
fulfilled by all patients. The body weight was also 
measured appropriately in each visit. 
 
Blood sampling and laboratory monitoring 
Overnight fasting blood samples were 
obtained at baseline, 6 and after 12 months follow-up 
from both untreated RA patients and the control 
group. Serum apolipoprotein B was measured by 
immune-nephelometry with the aid of a Behring 
Nephelometer BN100 and reagents (antibodies and 
calibrators) from Behring Diagnostics GmbH 
(Liederbach, Germany). C-reactive protein (CRP) was 
measured by nephelometry. 
 
Statistical analysis 
Statistical analysis was performed using 
Statistica software, ver 7.1. Due to the distribution 
which was not normal (according to Kolmogorov-
Smirnov test), the variable differences were tested 
using non-parametric tests (Wilcoxon Matched Pair 
Test or Friedman ANOVA test – Chi-Square). The 
correlation between parameters was analysed using 
the Pearson correlation coefficient. Significance was 
set up at p < 0.05. 
 
 
Results 
 
Patients and control groups who participated 
in our study were allocated several parameters such 
as: age, sex BMI (Body mass index), duration of 
illness, MHAQ, morning stiffness, the affected joints, 
swollen joints, VAS index, global doctor assessment, 
sedimentation rate of erythrocytes, CRP, and 
rheumatoid factor (RF). These parameters show 
disease activity in early studies (Table 1). 
Table 1: Patients and controls characteristics 
 RA (n = 80) Controls (n = 30) 
Age (year) 45.7 ± 9.8 45.2 ± 9.8 
Sex: M/F 80 F 6/24 
BMI (kg/m²) 22.3 ± 2.6 21.8 ± 2.2 
Duration of disease (month) 6.2 ± 16.6  
MHAQ (1-4) 1.5 ± 0.5  
Morning stiffness 111.4 ± 133.2  
Affected Joints 7.8 ± 7.1  
Swollen joints 5.2 ± 3.7  
VAS (0-10) 7.0 ± 2.1  
Global doctors’ assessment 4.5 ± 2.3  
Sedimentation rate(mm/h) 45.5 ± 30.3  
CRP (mg/1) 21.69 ± 29.4  
RF (positive/negative) 64/16  
BMI: Body Mass Index; MHAQ: Question modified to improve health 
VAS: visual analog (pain) score; CRP: C-reactive protein; RF: Rheumatoid factor. 
 
During the study, 80 patients with newly 
discovered active and untreated RA were treated with 
Methotrexate. These 80 patients were selected 
according to those who have responded to the 
therapy. The patients who did not respond to the 
therapy (7 in number) were excluded from the study. 
Figure 1 shows the DAS28 (Disease Activity 
Score in 28 joints) index at the beginning, after 6 and 
12 months of therapy. 
 
Figure 1: Disease activity score 28 (DAS28) at baseline, at 6, and 
12 months during the treatment 
 
At DAS28 score after 6 months for p < 0.01 
there are significant differences in relation beginning, 
6 and 12 months, the difference is significant (p < 
0.001), and also in the relation beginning/12 month 
there is also a significant difference. 
Table 2: Descriptive statistics / RA patients 
 Valid N Mean Confidence 
-95,00% 
Confidence 
+95,00% 
Minimum Maximum Std.Dev. 
CRP 0 m. 80 21.69 17.93 25.44 1.80 63.00 15.98 
CRP 6 m. 80 20.51 12.00 29.01 1.00 307.00 36.19 
CRP 12 m. 80 12.31 9.50 15.11 0.00 62.00 11.95 
Apo B 0m. 80 1.79 1.67 1.92 0.70 3.30 0.53 
Apo B 6 m. 80 1.79 1.67 1.92 0.60 3.50 0.54 
Apo B 12 m. 80 1.83 1.71 1.95 0.70 3.50 0.52 
CRP levels at baseline, at 6 months, and 12 months. 
 
As for CRP, there was a significant 
consecutive decrease from baseline, both at 6 and at 
12 months (for both variables, between each of time-
points; Friedman ANOVA; p < 0.001) (Table 3). 
Table 3: CRP levels at baseline, at 6 months, and 12 month 
 Average Rank Sum of Ranks Mean Std.Dev. 
CRP 0 m. 2.44 175.50 21.69 15.98 
CRP 6 m. 2.08 150.00 20.51 36.19 
CRP 12 m. 1.48 106.50 12.31 11.95 
Friedman ANOVA; Chi Sqr. (N = 80, df = 2) = 36.07, p = 0.000 
 
For Z = 5.16 and p < 0.001 (p = 0.000) 
average values of CRP after 12 months (x = 12.31 
mg/l) of therapy are significantly lower according to 
the values of CRP at the beginning (x = 21.69 mg//l) 
(Table 4). 
Table 4: CRP / CRP beginning & CRP 12 m 
Wilcoxon Matched Pairs Test 
 Valid T Z p-level 
CRP 0m. & CRP 12 m 80 361.50 5.16 0.000 
Apolipoprotein B (Apo B) levels at baseline, at 6 months, and at 12 months. 
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As for Apo B, there was no significant 
consecutive difference from baseline, both at 6 and at 
12 months (for both variables, between each of time-
points; Friedman ANOVA; p < 0.001) (Table 5). 
Table 5: Apo B levels at baseline, at 6 months, and 12 months 
 Average Rank Sum of Ranks Mean Std.Dev. 
Apo B 0 m. 1.90 136.50 1.79 0.53 
Apo B 6 m. 1.97 141.50 1.79 0.54 
Apo B 12 m. 2.14 154.00 1.83 0.52 
Friedman ANOVA; Chi Sqr. (N = 80, df = 2) = 2.80, p = 0.25. 
 
For Z = 0.94 and p > 0.05 (p = 0.35) average 
values of Apo B after 12 months (x = 1.83 g/l) of 
therapy were nonsignificantly higher according to the 
values of Apo B at the beginning (x = 1.79 g/l) (Table 
6). 
Table 6: Apo B / Apo B beginning & Apo B 12 m. 
 Wilcoxon Matched Pairs Test  
 Valid T Z p-level 
Apo B 0 m. & Apo B 12 m. 80 871.00 0.94 0.35 
Correlation in relation to CRP/Apo B. 
 
Comparing the results of CRP and Apo B at 
baseline, after 6 and 12 months we found a weak 
nonsignificant negative correlation about the values of 
CRP and Apo B at baseline and after 12 months (r = –
0.15 and r = -0.12, p > 0.05). In other words, the 
elevation of CRP by 1 mg/l was accompanied by a 
decrease of Apo B values by 0.005 g/l (Figure 2).  
  
Figure 2: Correlation of CRP and Apo B levels at baseline (left); 
Correlation of CRP and Apo B levels at 12 months (right) 
 
As for the relationship at 6 months, we found 
a moderately poor and weak insignificant correlation 
(p > 0.05). 
 
 
Discussion 
 
Our findings support the view that present 
chronic inflammation at RA patients affects the 
endothelium, and that, in association with 
atherosclerosis, it may be the mechanism that at least 
partly explains the increased mortality and morbidity 
occurring in patients with RA. Our goal was to 
determine the disease activity, values of CRP and 
Apo B lipoproteins in patients with active RA and 
DMARD-naïve RA patients before treatment and after 
6 and 12 months of treatment with DMARDs, 
respectively with MTX. The patients with active RA 
had nonsignificantly increased levels of Apo B after 6 
and 12 months of treatment with MTX. On the other 
hand, the values of acute phase reactant-CRP were 
lower after 6 months and one year of treatment. This 
suggests that moderate increasing levels of Apo B 
lipoproteins were accompanied by a decrease of 
inflammation at the end of the study.  
Several studies have suggested that CRP has 
direct effects on the vessel wall promoting 
atherosclerosis. An association between high-grade, 
chronic CRP elevation and subclinical atherosclerosis 
in patients with RA has been reported. Additionally, a 
higher risk of CV events in patients with RA with 
chronic inflammation expressed by persistently 
increased CRP serum levels has been found, 
although high-sensitive C-reactive protein is shown to 
have a strong relationship with recurrent events of 
CVD in several randomised clinical trials [21], [22], 
[23]. 
The clinical importance of dyslipidemia 
concerning CV events or death in RA is unclear. Even 
though there is observational data that suggests that 
there is no significant difference between RA and non-
RA subjects in the risk imparted by hyperlipidemia 
[21], it could be possible that non-traditional CVD risk 
factors, or other lipid parameters besides those found 
in cholesterol profiles, explain a greater proportion of 
CVD risk than in non-RA patients [24]. It has been 
proposed that the non-fasting apoB/apoA1 ratio was 
superior to any of the cholesterol ratios for estimation 
of the risk of acute myocardial infarction [25]. Some 
have suggested that the elevation in lipids after RA 
therapy might be offset by a reduction of more 
atherogenic molecules [26] such as apo B and apoA-I 
or total cholesterol. 
Importance of apo B is because of apo B 
presence in very low‐density lipoproteins (VLDL), 
intermediate‐density lipoproteins (IDL), large buoyant 
LDL and small dense LDL (sd‐LDL), with one 
molecule of Apo B in each of these atherogenic 
particles. Therefore, total apo B reflects the total 
number of potentially atherogenic particles and in the 
AMORIS study was find that apo B has a stronger 
relationship with risk of fatal MI and other CV events 
than does non‐HDL C [12], [15], [16]. Also, the report 
of the Uppsala Longitudinal Study of Adult Men 
(ULSAM), about these risk values correspond well 
with those found in the AMORIS study [27]. Same 
conclusions have been confirmed by many other 
studies (The EPIC‐Norfolk study, Nurses’ Health 
study, THROMBO study, GRIPS and Caerphilly 
studies, etc.) [12]. 
Katherine P. Liao report for a nonsignificant 
increase of apo B values and no significant correlation 
between change in CRP and apo B levels (r = 0.14, P 
= 0.20) and the atherogenic indices after treatment of 
RA patients [28]. At Sana P. study both Apo A1 and 
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Apo B are significantly lower in cases than in controls. 
Elevated Apo B levels indicate an increased risk of 
cardiovascular disease, but in their study, Apo B was 
23% decreased in cases when compared to controls 
[29]. In a similar study, Magarò M et al. have also 
shown Apo A1 and Apo B to be significantly lower in 
RA patients. They have also shown reduced levels of 
albumin in these patients which perhaps indicate a 
reduced rate of synthesis of proteins by the liver 
reflected in the decreased levels of the apoproteins 
[30]. A study by Eva Hurt Camejo et al., showed an 
Apo B decrease by 7 %, while other lipoproteins were 
in the normal range in the RA patients and similar to 
those in the controls [31]. 
According to the use of antirheumatic drugs in 
RA, tumour necrosis factor inhibitors and MTX are 
associated with a decreased risk of all CVEs while 
corticosteroids and NSAIDs are associated with an 
increased risk. Targeting inflammation with tumour 
necrosis factor inhibitors or methotrexate may have 
positive cardiovascular effects in RA [32]. In about 10 
comparative trials, a combination of MTX and a TNF-
alpha antagonist was more effective than MTX 
monotherapy on functional status and symptoms, 
especially in initially severe RA. In practice, MTX is 
the first-line antirheumatic drug and [33] MTX does 
not have any effect on the lipid profile of RA and 
Westlake et al., suggested that MTX use is associated 
with a reduced risk of CVD events in patients with RA. 
This may be important early in the disease course. 
The mechanism for this possible benefit cannot be 
fully determined from the current literature but, is likely 
to be multi-factorial. As disease control continues to 
improve in RA, future studies need to address the 
impact of MTX and other synthetic and biologics 
DMARDs on CVD, which remains the leading cause 
of death and a significant comorbidity in these patients 
[34] As we have presented in our study MTX was the 
initial treatment as a monotherapy but also chosen by 
most rheumatologists, which is in accordance with the 
EULAR and ACR guidelines [35]. 
Therefore, the expert opinion is: identifying 
the RA phenotype at greatest risk of CVD, 
understanding the interplay of increased traditional 
risk factors, common inflammatory processes and RA-
specific factors, and personalised use of DMARDs 
according to disease phenotype and comorbidity to 
reduce this risk are key areas for future research [32]. 
Limitations of Study: The sample size was 
small to allow for a generalisation of the results. The 
long-term effects of the treatment on lipids and 
disease activity can be deciphered only through 
further follow up. 
In conclusion, we examined the impact of 
Methotrexate on disease activity, values of C-reactive 
protein and the Apolipoprotein B at patients with 
Rheumatoid Arthritis. Eighty patients with active and 
newly discovered RA after a year of therapy achieved 
a significant decrease in the DAS28 (disease activity 
score) and CRP values. Changes in Apo B levels 
between the start and the end of the study were with 
nonsignificant differences. Levels of Apo B at the 12 
months were nonsignificantly higher compared to the 
results obtained at the beginning of the study. Use of 
MTX therapy at RA patients had a reduced effect on 
disease activity and inflammation, but nonsignificance 
effect on the values of Apo B lipoproteins. 
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